{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ikena Oncology, Inc."},"Symbol":{"label":"Symbol","value":"IKNA"},"Address":{"label":"Address","value":"645 SUMMER STREET,SUITE 101, BOSTON, Massachusetts, 02210, United States"},"Phone":{"label":"Phone","value":"+1 857 273-8343"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients."},"CompanyUrl":{"label":"Company Url","value":"https://www.ikenaoncology.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Caroline Germa","title":"Chief Medical Officer"},{"name":"David Damphousse","title":"Senior VP-Clinical Development Operations"},{"name":"Jotin Marango","title":"Chief Operating Officer & Chief Financial Officer"},{"name":"Mark Manfredi","title":"President, Chief Executive Officer & Director"},{"name":"Valdas Jurkauskas","title":"Senior Vice President-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}